CL2008003055A1 - Compuestos derivados del 5-oxo-4-fenil-4,5-dihidro-imidazol-1-il; procedimiento de preparacion; composicion farmaceutica, y su uso en, osteoporosis, drogas de abuso, enfermedad cardiovascular, entre otras, a travez de la modulacion del receptor npy y2. - Google Patents

Compuestos derivados del 5-oxo-4-fenil-4,5-dihidro-imidazol-1-il; procedimiento de preparacion; composicion farmaceutica, y su uso en, osteoporosis, drogas de abuso, enfermedad cardiovascular, entre otras, a travez de la modulacion del receptor npy y2.

Info

Publication number
CL2008003055A1
CL2008003055A1 CL2008003055A CL2008003055A CL2008003055A1 CL 2008003055 A1 CL2008003055 A1 CL 2008003055A1 CL 2008003055 A CL2008003055 A CL 2008003055A CL 2008003055 A CL2008003055 A CL 2008003055A CL 2008003055 A1 CL2008003055 A1 CL 2008003055A1
Authority
CL
Chile
Prior art keywords
npy
abuse
imidazol
osteoporosis
dihydro
Prior art date
Application number
CL2008003055A
Other languages
English (en)
Inventor
Orain
Y Nozulak David
Joachim
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2008003055A1 publication Critical patent/CL2008003055A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

Compuestos derivados del 5-oxo-4-fenil-4,5-dihidro-imidazol-1-il; procedimiento de preparación; composición farmacéutica, y su uso en, osteoporosis, drogas de abuso, enfermedad cardiovascular, entre otras, a través de la modulación del receptor npy y2.
CL2008003055A 2007-10-16 2008-10-16 Compuestos derivados del 5-oxo-4-fenil-4,5-dihidro-imidazol-1-il; procedimiento de preparacion; composicion farmaceutica, y su uso en, osteoporosis, drogas de abuso, enfermedad cardiovascular, entre otras, a travez de la modulacion del receptor npy y2. CL2008003055A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07118616 2007-10-16

Publications (1)

Publication Number Publication Date
CL2008003055A1 true CL2008003055A1 (es) 2009-06-05

Family

ID=39144610

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2008003055A CL2008003055A1 (es) 2007-10-16 2008-10-16 Compuestos derivados del 5-oxo-4-fenil-4,5-dihidro-imidazol-1-il; procedimiento de preparacion; composicion farmaceutica, y su uso en, osteoporosis, drogas de abuso, enfermedad cardiovascular, entre otras, a travez de la modulacion del receptor npy y2.

Country Status (9)

Country Link
US (1) US7786155B2 (es)
EP (1) EP2212295A2 (es)
JP (1) JP2011500633A (es)
CN (1) CN101827826A (es)
AR (1) AR068875A1 (es)
CL (1) CL2008003055A1 (es)
PE (1) PE20090818A1 (es)
TW (1) TW200922560A (es)
WO (1) WO2009050201A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011500632A (ja) * 2007-10-16 2011-01-06 ノバルティス アーゲー Ｎｐｙｙ２受容体モジュレーターとして有用なイミダゾリジン−２，４−ジオン（ヒダントイン）誘導体
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE910913A1 (en) 1990-03-20 1991-09-25 Sanofi Sa N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them
US5270317A (en) * 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
EP0640594A1 (en) 1993-08-23 1995-03-01 Fujirebio Inc. Hydantoin derivative as metalloprotease inhibitor
WO1997031910A1 (en) 1996-02-28 1997-09-04 Merck & Co., Inc. Fibrinogen receptor antagonists
DE19816929A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue substituierte Aminosäurederivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
AR035011A1 (es) 1999-06-30 2004-04-14 Daiichi Seiyaku Co Compuestos inhibidores de vla-4
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US7317025B2 (en) 2003-09-24 2008-01-08 Johnson & Johnson Pharmaceutical Research & Development, Llc Non-peptidic NPY Y2 receptor inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
WO2005090316A1 (en) 2004-03-12 2005-09-29 Wyeth HYDANTOINS HAVING RNase MODULATORY ACTIVITY
WO2005114201A1 (en) 2004-05-21 2005-12-01 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor npy2 (npy2)
ES2377446T3 (es) 2005-06-23 2012-03-27 Janssen Pharmaceutica Nv Derivados de imidazolinona e hidantoína como nuevos inhibidores de histona desacetilasa
TW200730523A (en) 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
EP1948629A1 (en) 2005-10-31 2008-07-30 Janssen Pharmaceutica N.V. Substituted piperazines and piperidines as modulators of the neuropeptide y2 receptor
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP2011500632A (ja) 2007-10-16 2011-01-06 ノバルティス アーゲー Ｎｐｙｙ２受容体モジュレーターとして有用なイミダゾリジン−２，４−ジオン（ヒダントイン）誘導体

Also Published As

Publication number Publication date
JP2011500633A (ja) 2011-01-06
TW200922560A (en) 2009-06-01
US20090099244A1 (en) 2009-04-16
WO2009050201A2 (en) 2009-04-23
US7786155B2 (en) 2010-08-31
CN101827826A (zh) 2010-09-08
WO2009050201A3 (en) 2009-08-13
EP2212295A2 (en) 2010-08-04
PE20090818A1 (es) 2009-07-24
AR068875A1 (es) 2009-12-09

Similar Documents

Publication Publication Date Title
BRPI0815709A2 (pt) composro, composição farmacêutica, e, uso de um composto.
BRPI0923500A2 (pt) uso e composição farmacêutica compreendendo agonista ou modulador do receptor s1p, e kit.
CL2009000171A1 (es) Compuestos derivados de 1-oxa-3-azaespiro, antagonistas del receptor y5 de neuropeptido y (npy); composicion farmaceutica que comprende dicho compuesto; y uso para el tratamiento de trastornos de la alimentacion, trastornos de la bebida, obesidad y depresion.
CL2007002642A1 (es) Compuestos derivados de 3-(6-oxo-1,6-dihidro-piridin-3-il)-benzamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2008001049A1 (es) Compuestos derivados de benzamidas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la diabetes, intolerancia a la glucosa, dislipidemia, hipertension, obesidad.
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
BRPI0814593A2 (pt) Composto, composição farmacêutica que o contém e uso do composto.
CL2006002831A1 (es) Compuestos derivados de sulfonamida: proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de una enfermedad mediada por el receptor de glucocorticoides.
CL2007002649A1 (es) Composicion farmaceutica que comprende 2-[6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil]-4-fluoro-benzonitrilo; y uso para el tratamiento de la diabetes.
EA201290984A1 (ru) Гелеобразные фармацевтические композиции, препятствующие злоупотреблению
CL2007002971A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BRPI0820997A2 (pt) Comprimidos de desintegração oral compreendendo difenidramina.
MY153975A (en) Pyridine derivatives as s1p1/edg1 receptor modulators
CL2008001994A1 (es) Compuestos derivados de pirazin-2-ona; combinacion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, aterosclerosis, hipertension, entre otras.
BR112012004335A2 (pt) composto, composição farmacêutica, e, uso do composto.
EA201001402A1 (ru) Фармацевтические растворы, способ получения и терапевтическое применение
CL2007002970A1 (es) Compuestos derivados de aminometil-4-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y su uso para tratar depresion, ansiedad, trastorno bipolar, entre otras.
DK2238110T3 (da) 5.6-bisaryl-2-pyridin-carboxamid-derivater, fremstilling heraf og terapeutisk anvendelse heraf som urotensin II-receptorantagonister
CL2008000304A1 (es) Compuestos derivados de 1-oxa-3-azaespiro[4.5]decan-2-ona; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de un trastorno de la alimentacion, obesidad, depresion.
EA200900958A1 (ru) Препарат невирапина пролонгированного высвобождения
DE502007005902D1 (de) -methyl-19-nor-20- spirox-4-en-3-one), sowie diese enthaltende pharmazeutische präparate
BRPI0717369A2 (pt) Composto, medicamento, composição farmacêutica que o contém e uso do composto.
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina